ABSTRACT

Over the last decade, both worlds of drug development and health care evaluations have undergone major changes impacting dramatically the way pharmaceutical companies envision their business models. One factor driving the drug development’s paradigm shift is the emergence of real-world evidence as a new but critical market access hurdle.